Tag

Amyloid

All articles tagged with #amyloid

health17 days ago•39 min saved

Alzheimer’s research shows real progress with new drugs and broader targets

After decades of slow progress, Alzheimer’s research is showing signs of turning a corner: two FDA-approved drugs (lecanemab and donanemab) that clear brain amyloid plaques may slow cognitive decline, while scientists are exploring additional targets like tau, inflammation, and GLP-1–based therapies that could reduce dementia risk by improving vascular health. Many treatments remain in early-stage trials, and controversial developments in China’s experimental surgery highlight both the field’s promise and its uncertainties as researchers pursue a future with a broader, more effective treatment toolkit.

via vox.com|

#alzheimers #amyloid #clinical-trials

health1 month ago•5 min saved

Kisunla therapy linked to surprising brain plaque clearance in Broward Alzheimer's patient

A 79-year-old Pompano Beach man, Scott Milinsky, became Florida’s second patient to receive Kisunla, Eli Lilly’s anti-amyloid Alzheimer’s drug, at Broward Health North. After 18 infusions over about 18 months, a final PET scan showed the brain’s amyloid plaques were cleared, offering hope by slowing cognitive decline—though it is not a cure since TAU tangles persist. The Broward Health center is treating more than 60 patients with Kisunla.

via Miami Herald|

#alzheimers #amyloid #broward

health2 months ago•8 min saved

Breathing Bursts May Help Clear Alzheimer's Proteins in the Awake Brain

Researchers presented at the Alzheimer’s Association International Conference that brief, wakeful CO2 bursts may stimulate the brain’s glymphatic system, aiding clearance of tau and raising blood beta-amyloid temporarily; findings from a small 12-person study also reference breath-centered practices like yoga as potential contributors, but more research is needed to determine if this could slow cognitive decline.

via HuffPost UK|

#amyloid #carbon-dioxide #dementia

science3 months ago•5 min saved

Massive brain-imaging study finds ethnic differences in Alzheimer's amyloid biology

A large-scale analysis of brain imaging from 17,017 older adults across five cohorts used the Centiloid standard to compare amyloid burden. The study found Hispanic participants generally have lower amyloid levels and a weaker link between APOE ε4 and amyloid than non-Hispanic whites with similar risk, implying Alzheimer’s biology may differ across populations and highlighting the need for diverse data to guide treatments.

via SciTechDaily|

#alzheimers-disease #amyloid #apoe-e4

health5 months ago•8 min saved

Two Early Windows for Dementia Signals Detected Decades Before Diagnosis

A Mayo Clinic study of 2,082 participants found two broad windows where dementia-related changes begin long before diagnosis: cognition and amyloid changes start in the 50s–60s, followed by tau changes and blood biomarkers (GFAP, NfL, p-tau) in the late 60s to early 70s, along with brain atrophy. This could enable earlier detection and screening approaches, even though no single test currently exists.

via HuffPost UK|

#amyloid #biomarkers #dementia

health5 months ago•6 min saved

Alzheimer's blood tests spark debate over predicting risk and guiding care

Alzheimer's blood tests that detect amyloid or tau are being considered for early risk assessment, but doctors say their predictive value for asymptomatic people is uncertain, with potential false positives/negatives and no clear benefit from early intervention; FDA has cleared two tests for symptomatic patients, not for screening; patient interest is high, with surveys showing many would take a test if advised, though distress is common.

via NBC News|

#alzheimers #amyloid #blood-tests

biotech5 months ago•2 min saved

Amyloid debates and peptide policy drive biotech news

FDA plans advisory panels to reconsider compounded peptides; a sweeping Cochrane review revives debates over amyloid-targeting Alzheimer’s drugs; Roche will run another Elevidys trial outside the U.S. as Sarepta markets it domestically; Lilly’s Foundayo GLP-1 pill shows non-inferiority to insulin glargine with a FDA submission planned by the end of Q2.

via statnews.com|

#alzheimers #amyloid #biotech

health5 months ago•4 min saved

Amyloid-targeting Alzheimer’s drugs fall short on patient benefit, review finds

A Cochrane review of 17 trials with over 20,000 people with mild cognitive impairment or early dementia found that seven anti-amyloid drugs, including donanemab and lecanemab, do not deliver a clinically meaningful benefit, even though they reduce brain amyloid. The findings challenge the idea that removing amyloid improves patient outcomes and have fueled ongoing debate over the amyloid hypothesis and the drugs’ high costs and risks.

via ScienceAlert|

#alzheimers #amyloid #clinical-trials

health5 months ago•4 min saved

New analysis questions real benefit of amyloid-clearing Alzheimer's drugs

A Cochrane Collaboration analysis of 17 trials involving over 20,000 people finds that amyloid-clearing Alzheimer's drugs slow decline but do not meaningfully improve patients’ lives, while carrying risks and costing up to £90,000 for an 18‑month course; the findings have sparked debate among experts, with some arguing for nuanced interpretation and others defending potential benefits, and the NHS continuing not to fund them.

via BBC|

#alzheimers #amyloid #cost

science6 months ago•7 min saved

Diversity Reveals Distinct Alzheimer's Biomarker Patterns

A large USC-led study from the HABS-HD cohort finds early Alzheimer’s biomarkers differ by race/ethnicity: Black and Hispanic participants showed higher tau in memory-related brain regions even when amyloid levels were similar to White participants, and the amyloid–cognition link varied by group. Scanner limitations and social determinants of health may also influence readings, underscoring the need for population-tailored diagnostics and more inclusive research.

via Neuroscience News|

#alzheimers-disease #amyloid #diverse-populations

science8 months ago•5 min saved

Lithium in the Brain Sparks a Ten-Year Alzheimer’s Breakthrough

Harvard researchers show lithium naturally exists in the brain and supports neuron function; lithium depletion is an early Alzheimer’s change and is reduced when amyloid plaques bind lithium. In mice, losing brain lithium accelerates disease, while a lithium orotate compound can prevent or reverse pathology, prompting planned clinical trials; researchers caution against self-medicating until trials establish safety and efficacy.

via Harvard Gazette|

#alzheimers-disease #amyloid #brain-aging

health1 year ago•5 min saved

C2N Diagnostics Launches Enhanced Blood Test for Early Alzheimer's Detection in Patients 50+

A new blood test for Alzheimer's disease, measuring tau and amyloid proteins, offers 90% accuracy in early detection, potentially transforming diagnosis and care by providing a faster, less invasive, and more accessible tool especially useful in primary care settings.

via Earth.com|

#alzheimers #amyloid #blood-test

health2 years ago•4 min saved

"Atrium Health Wake Forest Baptist Medical Center Leads Region in New Alzheimer's Drug Treatment"

Atrium Health Wake Forest Baptist in Winston-Salem has treated its first patient with the FDA-approved Alzheimer's medication, Lecanemab, marking the first Alzheimer's drug approval in over 20 years. The medication slows the progression of the disease by removing amyloid, a protein in the brain believed to contribute to memory loss. However, it is only effective for those with mild cognitive impairment or mild dementia due to Alzheimer's, and not for those with more advanced dementia.

via WXII12 Winston-Salem|

#alzheimers #amyloid #atrium-health-wake-forest-baptist

health2 years ago•4 min saved

"Revitalized Hope: Researchers Revisit Alzheimer's Vaccines Following Promising Drug Breakthrough"

Researchers are revisiting the development of vaccines for Alzheimer's disease following recent successes in drug treatments that remove toxic proteins from the brain. Clinical trials are underway or completed for at least seven Alzheimer's vaccines that target the disease-related proteins beta amyloid or tau. The renewed interest in vaccines comes after a promising first attempt over 20 years ago was abandoned due to life-threatening brain inflammation. Scientists believe they now understand what went wrong and are testing new vaccines that provoke an immune response without causing excess inflammation. Vaccines could offer a cheaper and easier-to-administer option for the millions of people affected by Alzheimer's.

via Reuters|

#alzheimers #amyloid #clinical-trials

health3 years ago•4 min saved

The Overhyped Reality of New Alzheimer's Drugs

The recent hype surrounding new Alzheimer's drugs that target amyloid, a protein thought to cause the disease, may be unwarranted. While these drugs have shown some ability to slow cognitive decline, the benefits are minimal and may not be noticeable to doctors or patients. Additionally, the drugs come with significant side effects, including brain bleeding and swelling, and are prohibitively expensive. The trials for these drugs were highly selective, excluding patients with other brain pathologies or medical problems, raising concerns about their effectiveness in real-world clinical settings. Furthermore, the drugs were tested on patients in the earliest stages of the disease, and even with amyloid clearance, patients still declined rapidly. Given these shortcomings, it may be time to explore alternative treatment options for dementia beyond the anti-amyloid drug pathway.

via The Conversation|

#alzheimers-disease #amyloid #dementia